Zogenix to Present at Leerink Swann 2012 Global Healthcare Conference

        Print
| Source: Zogenix

SAN DIEGO, Feb. 10, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that Stephen J. Farr, Ph.D., President and Chief Operating Officer, and Ann Rhoads, Executive Vice President and Chief Financial Officer, will be presenting at the Leerink Swann 2012 Global Healthcare Conference on February 16, 2012 in New York City.

Event: Leerink Swann 2012 Global Healthcare Conference
Date:  Thursday, February 16, 2012
Place:  New York City
Time:  2:00 pm ET

The presentation will be webcast live and archived for 90 days on Zogenix' Investor Relations website at www.ir.zogenix.com. Dr. Farr and Ms. Rhoads will also be available to participate in one-on-one meetings at the conference.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ (hydrocodone bitartrate), is a novel, oral, single-entity (without acetaminophen) extended-release capsule formulation currently in Phase 3 clinical trials for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix's second DosePro investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia.

INVESTORS:
Zack Kubow | The Ruth Group
646.536.7020 | 

MEDIA:
Victoria Aguiar | The Ruth Group
646.536.7013 |